SG Americas Securities LLC raised its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 46.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 306,287 shares of the company's stock after purchasing an additional 96,758 shares during the quarter. SG Americas Securities LLC owned about 0.13% of Cellebrite DI worth $5,951,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Gen Wealth Partners Inc acquired a new position in Cellebrite DI during the fourth quarter valued at approximately $85,000. NewEdge Advisors LLC lifted its holdings in shares of Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. Polen Capital Management LLC acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $222,000. Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $234,000. Finally, HighTower Advisors LLC acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $274,000. Institutional investors and hedge funds own 45.88% of the company's stock.
Wall Street Analyst Weigh In
CLBT has been the topic of a number of recent research reports. JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Needham & Company LLC reissued a "buy" rating and set a $24.00 price target on shares of Cellebrite DI in a research report on Friday, June 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and a consensus target price of $22.43.
Check Out Our Latest Stock Report on Cellebrite DI
Cellebrite DI Trading Up 1.0%
CLBT stock traded up $0.15 during trading on Monday, reaching $15.93. The stock had a trading volume of 1,548,038 shares, compared to its average volume of 1,476,218. Cellebrite DI Ltd. has a 1-year low of $11.47 and a 1-year high of $26.30. The firm has a fifty day moving average price of $18.10 and a 200 day moving average price of $19.92. The company has a market capitalization of $3.81 billion, a P/E ratio of -11.46, a PEG ratio of 4.27 and a beta of 1.32.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same quarter in the previous year, the firm posted $0.08 earnings per share. The company's revenue was up 20.0% compared to the same quarter last year. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles

Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.